131 related articles for article (PubMed ID: 38359408)
1. Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study.
Ikeda D; Oura M; Uehara A; Tabata R; Narita K; Takeuchi M; Machida Y; Matsue K
Blood Adv; 2024 Apr; 8(8):1893-1897. PubMed ID: 38359408
[No Abstract] [Full Text] [Related]
2. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
Wang S; Wang L; Hu J; Qian W; Zhang X; Hu Y; Zhu Q; Chen B; Wu D; Chang CH; Xu P; Zheng X; Wei J; Liu Y; Cui G; Tang Y; Ma Y; Huang H; Yi H; Zhao W
Cancer Commun (Lond); 2021 Mar; 41(3):229-239. PubMed ID: 33482051
[TBL] [Abstract][Full Text] [Related]
4. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
[TBL] [Abstract][Full Text] [Related]
5. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry.
Gang AO; Pedersen M; d'Amore F; Pedersen LM; Jensen BA; Jensen P; Møller MB; Mourits-Andersen HT; Pedersen RS; Klausen TW; de N Brown P
Leuk Lymphoma; 2015; 56(9):2556-62. PubMed ID: 25629994
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
7. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.
Sang W; Zhou H; Qin Y; Shen Z; Yan D; Sun C; Song X; Ma Y; Tu D; Bian Z; Nie S; Jin Y; Xu L; Li Z; Xu K
Int J Hematol; 2021 Aug; 114(2):189-198. PubMed ID: 33893987
[TBL] [Abstract][Full Text] [Related]
9. A promising prognostic model for predicting survival of patients with HIV-related diffuse large B-cell lymphoma in the cART era.
Chen J; Wu Y; Kang Z; Qin S; Ruan G; Zhao H; Tao X; Xie Z; Peng J
Cancer Med; 2023 Jun; 12(11):12470-12481. PubMed ID: 37081761
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
Salles G; de Jong D; Xie W; Rosenwald A; Chhanabhai M; Gaulard P; Klapper W; Calaminici M; Sander B; Thorns C; Campo E; Molina T; Lee A; Pfreundschuh M; Horning S; Lister A; Sehn LH; Raemaekers J; Hagenbeek A; Gascoyne RD; Weller E
Blood; 2011 Jun; 117(26):7070-8. PubMed ID: 21536860
[TBL] [Abstract][Full Text] [Related]
11. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
[TBL] [Abstract][Full Text] [Related]
13. Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience.
Patel DA; Johanns TM; Trinkaus K; Bartlett NL; Wagner-Johnston N; Cashen AF
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):806-811. PubMed ID: 31648954
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
Lee H; Kim YR; Kim SJ; Park Y; Eom HS; Oh SY; Kim HJ; Kang HJ; Lee WS; Moon JH; Won YW; Kim TS; Kim JS
Ann Hematol; 2017 Nov; 96(11):1873-1881. PubMed ID: 28831584
[TBL] [Abstract][Full Text] [Related]
15. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F
J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
[TBL] [Abstract][Full Text] [Related]
16. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D; Asai H; Maeda Y; Shinagawa K; Ikeda K; Yokoyama M; Terui Y; Takeuchi K; Yoshino T; Matsuo K; Hatake K; Tanimoto M
Ann Oncol; 2010 Jun; 21(6):1217-1221. PubMed ID: 19884246
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
18. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
19. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China.
Li X; Xu Q; Gao C; Yang Z; Li J; Sun A; Wang Y; Lei H
Ann Hematol; 2023 Dec; 102(12):3465-3475. PubMed ID: 37615680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
